Betta Pharma signs China deals with InventisBio, Merus

InventisBio Inc. (Shanghai, China) granted Betta Pharmaceuticals Co. Ltd (SZSE:300558) exclusive rights to develop and commercialize D-0316 in China, including Hong Kong and Taiwan.

InventisBio will receive an upfront payment and R&D milestones totaling RMB230 million ($33.5 million), and is eligible for sales milestones and tiered royalties based on annual sales...